Skip to content
Study details
Enrolling now

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Nested Therapeutics, Inc
NCT IDNCT06326411ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

230

Study length

about 5.6 years

Ages

18+

Locations

17 sites in CA, CO, CT +7

About this study

Researchers are testing a treatment called NST-628 for adults with solid tumors that have not responded to other treatments. The trial will evaluate how safe and effective this treatment is.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take NST-628
PhasePhase 1
Primary goalPart B: Evaluate objective tumor response rate

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Part B: Evaluate objective tumor response rate

Secondary: Part A and B: Characterize the pharmacokinetics of NST-628, Part A and B: Evaluate overall survival (OS), Part A and B: Evaluate progression free survival (PFS), Part A: Evaluate objective tumor response rate

Body systems

Oncology